About Livivos LiverScope® is the revolutionizing tool to do it, by transforming the way the disease is diagnosed and managed Livivos aims to halt the ominous worldwide growth of liver disease

Welcome to Livivos, Inc.

Livivos is leading the way in accurate Point-of-Care liver disease diagnosis, revolutionizing disease detection, grading, and management. Our innovative solution meets the growing demand for fast, accurate NAFLD and NASH diagnosis. LiverScope® has the potential to streamline drug efficacy trials and greatly expand access to accurate diagnostics.

With expertise in Magnetic Resonance and medical devices, and collaboration with hepatologists and diagnostic experts, Livivos is dedicated to improving human health.

Our Vision

Our vision is to enhance human health by revolutionizing the diagnosis and treatment of liver disease through cutting-edge technology.

Our Goal

Our goal is to democratize liver disease diagnosis by making accurate point-of-care testing broadly available.

The Path to LiverScope®

Compact Open Magnetic ResonanceNMR MOUSE

Portable Magnetic Resonance probes for industrial applications are developed in Germany.

Volume Selective Open Magnetic ResonanceSINGLE SIDED MAGNETIC RESONANCE ADVANCES

Use of the open Magnetic Resonance concept to select sensitive volumes outside of the magnet and antenna. Work led by teams in the US and Germany.

Concept DevelopmentLIVER DIAGNOSIS CONCEPT

Open Magnetic Resonance method for human tissue: skin inspection and liver diagnostic concept. Collaborations between Dr. Pablo Prado and MGH-Boston.

Liver Disease Scanner ConceptPATENT FILING

Livivos’s Point-of-Care diagnosis – intellectual property described in first patent.

LiverScope® DevelopmentMETHOD VALIDATION

LiverScope®, first fully functional scanner is validated using MRI liver fat standards -Calimetrix. (LiverScope® has not been cleared by the FDA.)

Clinical PerformanceIN-VIVO LIVER EXAMINATION

Completion of UC San Diego study demonstrating LiverScope®‘s market-leading performance for Point-of Care liver fat diagnosis.

Human Study. NIH Funding. Pharma EvaluationFAVORABLE COMPARISON TO GOLD STANDARD

Clinical study published in Magnetic Resonance in Medicine. NIH Grant awarded. Usage Agreement signed by Pfizer.

The people driving Livivos’s revolutionary diagnostics

Key Members

Pablo J Prado, PhD
– CEO, CTO

Dr. Prado is an accomplished tech leader with extensive expertise in the medical device and security industries. He has a proven track record of successful startup formation and product development, having served as the product introduction lead for 5 products currently in the market. He was the founder and CEO of ORS and One Resonance, and the President of Turbospec. He has also held senior management positions at Quasar Federal Systems, Progression Inc., T2 Biosystems, GE, and Quantum Magnetics. With a PhD in Physics, Dr. Prado is highly regarded in the scientific community and has served as a reviewer for several esteemed journals including the Journal of Magnetic Resonance, Journal of Applied Magnetic Resonance, and IEEE Journal of Solid-state Circuits.  He holds 10 patents, has authored 2 book chapters, and published over 40 scientific articles. See LinkedIn Profile.

Claude Sirlin, MD
– Chief Medical Officer

Claude B. Sirlin, MD, is an Associate Professor of Radiology at the University of California, San Diego (UCSD). He received his BA in Biology from Harvard University and his MD from UC San Francisco. He completed residency training in Diagnostic Radiology at UCSD and fellowship training in cross-sectional body imaging (MR, CT, US) at Stanford University. He is Chief of Body MRI, Head of the Liver Imaging Research Group, and Head of Clinical Research, Division of Body Imaging at UCSD – focused on MRI of liver cancer and diffuse liver disease. He has published more than 30 papers, 5 book chapters, 65 scientific abstracts, and 50 educational exhibits, and he reviews for 5 scientific journals. In 2004, Dr. Sirlin formed the UCSD Liver Imaging Group to develop new techniques for liver imaging. The Group actively collaborates with hepatologists, liver surgeons, and pathologists. Dr. Sirlin’s specific areas of interest are liver cancer and diffuse liver disease (fibrosis, fat, and inflammation).

Robert Lown
– Systems Engineering Lead

Mr. Lown is a world expert in the design and fabrication of compact permanent magnets for Magnetic Resonance and MRI devices. He has over 30 years of experience with 3D solid modeling, thermal analysis, structural design, manufacturing methods, and trouble-shooting of complex electromechanical systems. Mr. Lown has an M.S. in Mechanical Engineering. He has been the engineering lead for clinical MRI product development and several custom state of the art magnetic and mechanical assemblies for institutions such as JPL, Lawrence Berkeley National Laboratory, Los Alamos National Laboratory, Lawrence Livermore National Laboratory, and CERN. He was the Lead Engineer at ORS, Aster Enterprises, Dec-E-Tech, and Field Effects (Intermagnetics General Corp).

Ariel Feldstein, MD
– Hepatology Advisor. Chief Gastroenterology and Hepatology, Rady Children’s Hospital

Dr. Feldstein is Chief of the Gastroenterology, Hepatology & Nutrition Division at Rady Children’s Hospital-San Diego and a Professor of Pediatrics at UC San Diego School of Medicine. After graduating from the Univ. of Buenos Aires and completing a postdoctoral program in physiology at the Mayo Clinic, Dr. Feldstein went on to become the Director of Research for the Pediatric Institute at the Cleveland Clinic before moving to San Diego in 2011. Dr. Feldstein has published over 170 peer-reviewed publications, including articles in Nature, Journal of Clinical Investigation, Gastroenterology, Hepatology, Gut, Journal of Hepatology, Journal of Biological Chemistry, and Journal of Immunology. His research laboratory has provided key evidence regarding the role of cell death, innate immune activation, and inflammatory responses during chronic liver injury and carcinogenesis. He is an innovator and an entrepreneur, being the founder of two Biotech Companies, Torrey Pines Metabolic Health Labs and Jecure Therapeutics (acquired by Genentech/Roche in 2018).

Corporate & Intellectual Property

Adam Shipley
– Corporate Law Attorney

Mr. Shipley is a partner in Sheppard Mullin’s Corporate Practice Group. He advises buyers and sellers in acquisition of company, growth capital, and cross border transactions. He is a practical minded lawyer, who focuses in every matter on solving problems and getting deals done efficiently and in a manner that best promotes his client’s commercial objectives. Mr. Shipley has deep experience in the industrial, healthcare, life sciences, and energy sectors. He also has extensive experience in transactions involving cross border matters. He has been honored as a San Diego Rising Star, Super Lawyers, 2016-2019.

Jesse A. Salen
– Intellectual Property Attorney

Mr. Salen is an associate in the Intellectual Property Practice Group at Sheppard Mullin. He focuses his practice on trademark and patent prosecution, in addition to intellectual property licensing in the areas of healthcare information technology, software, medical devices, optics, nanotechnology, computer devices, and data storage. Mr. Salen has 16 years of business and technology experience, in both the healthcare and data storage industries. He was the Chief Technology Officer at ONRAD, Inc., a product manager at GE Healthcare, a manager of the customer care program at Hitachi Data Systems, a systems engineer at Memorial Sloan-Kettering Cancer Center, and a research and development engineer in the field of optics and nanotechnology at Micrion Corporation. He has published multiple peer-reviewed articles in the optics and nanotechnology fields, as well as numerous healthcare business journal articles.